Now showing items 1-17 of 17

    • Altered Gene Expression in Blood and Sputum in COPD Frequent Exacerbators in the ECLIPSE Cohort 

      Singh, Dave; Fox, Steven M.; Tal-Singer, Ruth; Bates, Stewart; Riley, John H.; Celli, Bartolome (Public Library of Science, 2014)
      Patients with chronic obstructive pulmonary disease (COPD) who are defined as frequent exacerbators suffer with 2 or more exacerbations every year. The molecular mechanisms responsible for this phenotype are poorly understood. ...
    • The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life 

      Dal Negro, Roberto W.; Celli, Bartolome R. (BioMed Central, 2016)
      Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition which is characterized by a dramatic socio-economic impact. Several indices were extensively investigated in order to asses the mortality ...
    • Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease 

      Kelly, Emer; Owen, Caroline A; Abraham, Amadeus; Knowlton, David L; Celli, Bartolome R; Pinto-Plata, Victor (F1000Research, 2013)
      Purpose: The development of novel biomarkers is an unmet need in chronic obstructive pulmonary disease (COPD). Arterial blood comes directly from the lung and venous blood drains capillary beds of the organ or tissue ...
    • A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease 

      Menche, Jörg; Sharma, Amitabh; Cho, Michael H; Mayer, Ruth J; Rennard, Stephen I; Celli, Bartolome; Miller, Bruce E; Locantore, Nick; Tal-Singer, Ruth; Ghosh, Soumitra; Larminie, Chris; Bradley, Glyn; Riley, John H; Agusti, Alvar; Silverman, Edwin K; Barabási, Albert-László (BioMed Central, 2014)
      Background: An important step toward understanding the biological mechanisms underlying a complex disease is a refined understanding of its clinical heterogeneity. Relating clinical and molecular differences may allow us ...
    • Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study 

      Almagro, Pere; Martinez-Camblor, Pablo; Soriano, Joan B.; Marin, Jose M.; Alfageme, Inmaculada; Casanova, Ciro; Esteban, Cristobal; Soler-Cataluña, Juan J.; de-Torres, Juan P.; Celli, Bartolome R.; Miravitlles, Marc (Public Library of Science, 2014)
      Background: FEV1 is universally used as a measure of severity in COPD. Current thresholds are based on expert opinion and not on evidence. Objectives: We aimed to identify the best FEV1 (% predicted) and dyspnea (mMRC) ...
    • A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease 

      Hardin, Megan; Cho, Michael H.; McDonald, Merry-Lynn; Wan, Emily; Lomas, David A.; Coxson, Harvey O.; MacNee, William; Vestbo, Jørgen; Yates, Julie C.; Agusti, Alvar; Calverley, Peter MA; Celli, Bartolome; Crim, Courtney; Rennard, Stephen; Wouters, Emiel; Bakke, Per; Bhatt, Surya P; Kim, Victor; Ramsdell, Joe; Regan, Elizabeth A.; Make, Barry J.; Hokanson, John E.; Crapo, James D.; Beaty, Terri H.; Hersh, Craig P. (2015)
      Short-acting β2-agonist bronchodilators are the most common medications used in treating chronic obstructive pulmonary disease (COPD). Genetic variants determining bronchodilator responsiveness (BDR) in COPD have not been ...
    • Health Status in the TORCH Study of COPD: Treatment Efficacy and Other Determinants of Change 

      Jones, Paul W; Anderson, Julie A.; Calverley, Peter MA; Celli, Bartolome R; Ferguson, Gary T; Jenkins, Christine; Yates, Julie C; Vestbo, Jorgen; Spencer, Michael D (BioMed Central, 2011)
      Background: Little is known about factors that determine health status decline in clinical trials of COPD. Objectives: To examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone propionate ...
    • Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer? 

      Polverino, Francesca; Laucho-Contreras, Maria; Rojas Quintero, Joselyn; Divo, Miguel; Pinto-Plata, Victor; Sholl, Lynette; de-Torres, Juan P.; Celli, Bartolome R.; Owen, Caroline A. (BioMed Central, 2016)
      Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by an excessive activation of the adaptive immune system and, in particular, uncontrolled expansion of the B-cell pool. One of the key promoters of ...
    • Inflammatory and Repair Serum Biomarker Pattern. Association to Clinical Outcomes in COPD 

      Casanova, Ciro; Müllerova, Hana; de Torres, Juan P; Corado, Henneth; Varo, Nerea; Cordoba, Elizabeth; Zeineldine, Salah; Paz, Hildegarde; Baz, Rebeca; Cortopassi, Felipe; Pinto-Plata, Victor Manuel; Divo, Miguel Jose; Celli, Bartolome R (BioMed Central, 2012)
      Background: The relationship between serum biomarkers and clinical expressions of COPD is limited. We planned to further describe this association using markers of inflammation and injury and repair. Methods: We studied ...
    • Is COPD a Progressive Disease? A Long Term Bode Cohort Observation 

      de-Torres, Juan P.; Marín, Jose M.; Pinto-Plata, Víctor; Divo, Miguel; Sanchez-Salcedo, Pablo; Zagaceta, Jorge; Zulueta, Javier J.; Berto, Juan; Cabrera, Carlos; Celli, Bartolome R.; Casanova, Ciro (Public Library of Science, 2016)
      Background: The Global Initiative for Obstructive Lung Diseases (GOLD) defines COPD as a disease that is usually progressive. GOLD also provides a spirometric classification of airflow limitation. However, little is known ...
    • Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis 

      Scott, David A; Woods, Bethan; Thompson, Juliette C; Clark, James F; Hawkins, Neil; Chambers, Mike; Celli, Bartolome R.; Calverley, Peter (BioMed Central, 2015)
      Background: Increasing evidence suggests pharmacological treatments may impact on overall survival in Chronic Obstructive Pulmonary Disease (COPD) patients. Individual clinical trials are rarely powered to detect mortality ...
    • Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report 

      Agusti, Alvar; Anderson, Wayne; Bakke, Per S; Barnes, Kathleen C; Barr, R Graham; Bleecker, Eugene R; Boezen, H Marike; Burkart, Kristin M; Cookson, William OC; Croxton, Thomas; Daley, Denise; Gan, Weiniu; Garcia-Aymerich, Judith; Hall, Ian P; Hansel, Nadia N; Kalsheker, Noor; Kiley, James P; Lambrechts, Diether; Lee, Sang-Do; Lomas, David A; London, Stephanie J; Nishimura, Masaharu; Postma, Dirkje S; Puhan, Milo A; Tesfaigzi, Yohannes; Tobin, Martin D; Vogelmeier, Claus; Wouters, Emiel; Ziegler-Heitbrock, Loems; MacNee, William; Crapo, James D; Vestbo, Jørgen; Silverman, Edwin Kepner; Cho, Michael Hyosang; Celli, Bartolome R; Demeo, Dawn Lisa; Hersh, Craig Palmer; Wilk, Jemma B; Nørdestgaard, Borge G.; Young, Robert P.; O'Donnell, Christopher J.; Kim, Woo Jin; Litonjua, Augusto Ampil (Informa Healthcare, 2011)
    • Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype 

      Agustí, Alvar; Edwards, Lisa D.; Rennard, Stephen I.; MacNee, William; Tal-Singer, Ruth; Miller, Bruce E.; Vestbo, Jørgen; Lomas, David A.; Calverley, Peter M. A.; Wouters, Emiel; Crim, Courtney; Yates, Julie C.; Coxson, Harvey O.; Bakke, Per; Mayer, Ruth J.; Silverman, Edwin Kepner; Celli, Bartolome R. (Public Library of Science, 2012)
      Background: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence ...
    • Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD 

      Nakajima, Takahiro; Nakamura, Hidetoshi; Owen, Caroline A.; Yoshida, Shuichi; Tsuduki, Keishi; Chubachi, Shotaro; Shirahata, Toru; Mashimo, Shuko; Nakamura, Miho; Takahashi, Saeko; Minematsu, Naoto; Tateno, Hiroki; Fujishima, Seitaro; Asano, Koichiro; Celli, Bartolome R.; Betsuyaku, Tomoko (Hindawi Publishing Corporation, 2016)
      Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function ...
    • Reliability of FEV1/FEV6 to Diagnose Airflow Obstruction Compared with FEV1/FVC: The PLATINO Longitudinal Study 

      Perez-Padilla, Rogelio; Wehrmeister, Fernando C.; Celli, Bartolome R.; Lopez-Varela, Maria Victorina; Montes de Oca, Maria; Muiño, Adriana; Talamo, Carlos; Jardim, Jose R.; Valdivia, Gonzalo; Lisboa, Carmen; Menezes, Ana Maria B. (Public Library of Science, 2013)
      QUESTION A 6-second spirometry test is easier than full exhalations. We compared the reliability of the ratio of the Forced expiratory volume in 1 second/Forced expiratory volume in 6 seconds (FEV1/FEV6) to the ratio of ...
    • Sexually-dimorphic targeting of functionally-related genes in COPD 

      Glass, Kimberly; Quackenbush, John; Silverman, Edwin K; Celli, Bartolome; Rennard, Stephen I; Yuan, Guo-Cheng; DeMeo, Dawn L (BioMed Central, 2014)
      Background: There is growing evidence that many diseases develop, progress, and respond to therapy differently in men and women. This variability may manifest as a result of sex-specific structures in gene regulatory ...
    • Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study 

      Sood, Akshay; Petersen, Hans; Qualls, Clifford; Meek, Paula M.; Vazquez-Guillamet, Rodrigo; Celli, Bartolome R.; Tesfaigzi, Yohannes (BioMed Central, 2016)
      Background: Spirometrically-defined chronic obstructive pulmonary disease (COPD) is considered progressive but its natural history is inadequately studied. We hypothesized that spirometrically-defined COPD states could ...